FDA Approved First Injectable for Alexander Disease
The newly authorized drug Zanvastro treats the rare genetic condition by suppressing toxic protein buildup.
Updated on Oct. 8, 2026 in Alzheimer’s
Live Poll
Should government prioritize funding for research into rare diseases over relying on private fundraising efforts?
On September 3, 2026, the FDA approved Zanvastro, the first injectable treatment for Alexander Disease, a rare genetic condition. The medication is designed for patients affected by the rare disorder, which leads to toxic protein accumulation in the brain.
Why it matters
The drug offers a new approach for managing Alexander Disease, which causes the deterioration of the myelin sheath in the brain due to excess GFAP protein. This approval provides a first-ever treatment option for patients who previously lacked clinical interventions for this condition.
In clinical trials, Zanvastro demonstrated the ability to preserve motor function over a one-year period compared to baseline disease progression. The medication is currently approved for use via injection into the cerebrospinal fluid.
The players
Ionis Pharmaceuticals
A biotechnology company specializing in RNA-targeted therapies and the developer of the GFAP-suppressing antisense technology used in Zanvastro.
Waisman Center
A multidisciplinary research facility that served as the primary site for developing mouse models to study GFAP gene expression.
The details
Alexander Disease is caused by a single-nucleotide mutation in the GFAP gene, which results in the production of excess protein and the buildup of Rosenthal Fibers. Zanvastro utilizes antisense technology that binds to messenger RNA to prevent the translation of this gene. By lowering the excess protein levels, the treatment aims to reduce the degradation of the myelin sheath, the protective layer surrounding nerve fibers in the brain.
Timeline
The research team received an NIH grant for drug repurposing between 2005 and 2007.
The Ramon family began fundraising for research efforts in 2008.
Researchers began using antisense technology to suppress GFAP in 2013.
The FDA approved the drug Zanvastro on September 3, 2026.
Health Landscape
The development of Zanvastro represents the successful translation of foundational mouse model research conducted at the Waisman Center into a clinical therapeutic. It reflects a shift toward gene-specific antisense treatments for rare neurological conditions.
Patients and families affected by Alexander Disease should consult their neurologist or specialist to understand if this new therapy is appropriate for their specific case. Clinical decisions regarding the use of this injection should be discussed with a physician to weigh the potential benefits.
The takeaway
Zanvastro provides a new, gene-targeted approach to treating the underlying cause of Alexander Disease. Patients should work closely with a specialist to discuss the role of this new therapy in their care plan as clinical experience with the drug grows.
Further reading
For additional context on research developments for rare neurological disorders, visit our Alzheimer’s section.
Source note: This article includes information reported by UW-Madison Police Department actively investigating three sexual assault cases - The Daily Cardinal.
Live Poll
Should government prioritize funding for research into rare diseases over relying on private fundraising efforts?
